Latest

COVID-19 vaccine

·March 23, 2020·3 min read

Tuberculosis BCG-based vaccine may be effective against COVID-19

VPM1002, a vaccine candidate based on the tuberculosis BCG vaccine, may be effective in protecting against COVID-19. Previous studies in mice have shown the BCG vaccine is effective at protecting against several respiratory viral infections. If effective against coronavirus, researchers hope the vaccine can bridge the time gap until a specific SARS-CoV-2 vaccine is available.

Featured Neuroscience

·March 21, 2020·2 min read

New vaccine candidate for COVID-19 identified

Researchers report they have identified a vaccine candidate for COVID-19 and are working towards phase one clinical testing. A chimpanzee adenovirus vaccine vector was chosen as the most suitable vaccine technology for SARS-CoV-2 as it can generate a stronger immune response in one dose and is not a replicating virus.

Featured Neuroscience

·March 16, 2020·5 min read

Designing a coronavirus vaccine: Researchers prepare for next year and beyond

Researchers are making progress in developing potential vaccines for coronavirus infections. While a vaccine for COVID-19 might be over a year away from market, researchers are looking ahead to attempt to prevent future outbreaks.

This shows a man in an empty parking lot

Featured Neuroscience

·March 16, 2020·4 min read

COVID-19 ‘Worry about 4 weeks from now,’ researchers warn

With the peak of COVID-19 cases occurring between 3.5 to four weeks after controlled interventions were put into place in China, US researchers are urging the public to ramp up social distancing efforts and increase testing immediately.

Featured Neuroscience

·March 16, 2020·8 min read

NIH Clinical Trial of Investigational Vaccine for COVID-19 Begins

A phase 1 trial evaluating an investigational vaccine designed to protect against COVID-19 has begun in Seattle. The study will enroll 45 healthy people aged 18 to 55, over approximately 6 weeks. The first participant received the investigational vaccine today. Adults in the Seattle area may join the study.